Ranibizumab and the eye

descriptionPublicationkeyboard_double_arrow_right Article 22 Feb 2011 English Publisher:CMA Joule Inc.Journal:Canadian Medical Association Journal, volume 183, pages 822-822 (issn: 0820-3946, eissn: 1488-2329,

Copyright policy )

Authors: Jason, Noble; Varun, Chaudhary;

doi: 10.1503/cmaj.090574

pmid: 21343272

pmc: PMC3080533

Ranibizumab and the eye

- Summary
- Subjects
- Metrics

Abstract

Ranibizumab is a recombinant, monoclonal antibody fragment that inhibits vascular endothelial growth factor (known as a VEGF-A inhibitor).1 Because it costs about 10 times more than bevacizumab,2 an anti-VEGF agent approved for intravenous use in metastatic colon cancer, ophthalmologists may choose

Related Organizations

University of Toronto
Canada

Keywords

Ranibizumab, Visual Acuity, Wet Macular Degeneration, Antibodies, Monoclonal, Humans, Antibodies, Monoclonal, Humanized, Injections

Impact byBIP!

	selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	0
	popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.	Average
	influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	Average
	impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.	Average